While SCD is a known therapeutic target that has been explored for a diverse set of lipid-based or metabolic disorders, such as diabetes, obesity, NASH, and cancer [6, 17], the above-described studies were the first to link SCD as a therapeutic target for synucleinopathies. This evidence concerns the gene SCD and diabetes mellitus.